Pancragen vs Tesofensine
A side-by-side research comparison of Pancragen and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pancragen | Tesofensine |
|---|---|---|
| Full name | Pancragen (Lys-Glu-Asp-Trp Pancreas Bioregulator) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound (peptide bioregulator) | Phase 3 Clinical Trial |
| Mechanism | As a signal peptide (Lys-Glu-Asp-Trp), it is proposed to regulate gene expression in pancreatic tissue, supporting normal endocrine and exocrine pancreatic function and carbohydrate metabolism. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | ~575 Da | 329.4 Da |
| Half-life | Short (peptide) | 8-10 days |
| Bioavailability | Oral (encapsulated) or subcutaneous | High (oral ~93%) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 0.25-0.5 mg |
| Frequency | Once daily | Once daily |
| Route | Oral capsule or subcutaneous | Oral |
Pancragen reported benefits
- Pancreatic tissue support
- Carbohydrate metabolism support (proposed)
- Metabolic resilience
- Short course-based protocol
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.